Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (>= 75) patients

Alkan A., GÜÇ Z. G. , Gurbuz M., ozgun G., Degirmencioglu S., Dogan M., ...More

JOURNAL OF MENS HEALTH, vol.17, pp.128-134, 2021 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 17
  • Publication Date: 2021
  • Doi Number: 10.31083/jomh.2021.041
  • Title of Journal : JOURNAL OF MENS HEALTH
  • Page Numbers: pp.128-134
  • Keywords: Metastatic castration-resistant prostate cancer, Enzalutamide, Abiraterone Acetate, Elderly, CHEMOTHERAPY, DOCETAXEL, SURVIVAL, OUTCOMES, SAFETY, MEN


Introduction: The efficacy and tolerability of Enzalutamide and Abiraterone Acetate have been reported in elderly patients with metastatic castration resistant prostate cancer (mCRPC). However, there is no randomized study directly comparing antitumor effects between these 2 agents in geriatric patients. We aimed to evaluate the efficacy of Enzalutamide (ENZA) and Abiraterone Acetate (AA) as a first-line treatment of mCRPC in elderly patients.